Lead Product(s) : Ziritaxestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
Details : The decision is based on the recommendations of the Independent Data Monitoring Committee (IDMC). Patients continued on their standard of care background treatment and were randomized on to either 200 mg or 600 mg ziritaxestat once daily or placebo.
Product Name : GLPG1690
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : Ziritaxestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable